Initial serum tumor marker change predicts progression-free and overall survival in immune checkpoint blockade treated non-small cell lung cancer

被引：0
|
作者：
Lang, David [1 ]
Horner, Andreas [1 ]
Brehm, Elmar [1 ]
Romain, Silas [2 ]
Kaiser, Bernhard [1 ]
Lamprecht, Bernd [1 ]
机构：
[1] Kepler Univ Hosp, Dept Pulmonol, Linz, Austria
[2] Johannes Kepler Univ Linz, Fac Med, Linz, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2018年 / 130卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P44
引用
收藏
页码：618 / 619
页数：2
相关论文
共 50 条
  • [1] Overall Survival in Elderly Metastatic Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade
    Simoes, M. F.
    Medeiros, M. F.
    Maciel Santana, D.
    De Andrade Souza, C. I.
    Mendes Gomes, L. B.
    De Freitas, H.
    Petrocchi Corassa, M.
    Spina Donadio, M. D.
    De Lima, V. C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S290 - S290
  • [2] Increasing progression-free survival in non-small cell lung cancer
    不详
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (09) : 498 - 498
  • [3] Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Memmott, Regan M.
    Wolfe, Adam R.
    Carbone, David P.
    Williams, Terence M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1086 - 1098
  • [4] Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study
    Philippe Thuillier
    Claire Joly
    Zarrin Alavi
    Geneviève Crouzeix
    Renaud Descourt
    Gilles Quere
    Véronique Kerlan
    Nathalie Roudaut
    [J]. Cancer Immunology, Immunotherapy, 2021, 70 : 2023 - 2033
  • [5] Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study
    Thuillier, Philippe
    Joly, Claire
    Alavi, Zarrin
    Crouzeix, Genevieve
    Descourt, Renaud
    Quere, Gilles
    Kerlan, Veronique
    Roudaut, Nathalie
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) : 2023 - 2033
  • [6] Baseline systemic inflammatory immune index may predict overall survival and progression-free survival in patients with non-small cell lung cancer patients on immune checkpoint inhibitors.
    Palmer, John P.
    Cao, Yenong
    Ibrahim, Samer
    Dhawan, Natasha
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer
    Zhao, Shen
    Zhang, Zhonghan
    Zhang, Yaxiong
    Hong, Shaodong
    Zhou, Ting
    Yang, Yunpeng
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2854 - 2866
  • [8] A 9-Gene Inflammation Signature Predicts Survival and Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Al-Bzour, N. N.
    Al-Bzour, A. N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S176 - S177
  • [9] Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer
    Komaki, Ritsuko
    Allen, Pamela K.
    Wei, Xiong
    Blumenschein, George R.
    Tang, Ximing
    Lee, J. Jack
    Welsh, James W.
    Wistuba, Ignacio I.
    Liu, Diane D.
    Hong, Waun Ki
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (02): : 317 - 324
  • [10] Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab
    Taniguchi, Yoshihiko
    Tamiya, Akihiro
    Isa, Syun-Ichi
    Nakahama, Kenji
    Okishio, Kyoichi
    Shiroyama, Takayuki
    Suzuki, Hidekazu
    Inoue, Takako
    Tamiya, Motohiro
    Hirashima, Tomonori
    Imamura, Fumio
    Atagi, Shinji
    [J]. ANTICANCER RESEARCH, 2017, 37 (10) : 5857 - 5862
12345